Skip to main content
Data Resources

AMP PD Knowledge Platform

​The Accelerating Medicines Partnership Parkinson’s disease (AMP PD) Knowledge Platform is a tool to explore and analyze whole genome sequencing, transcriptomics, and harmonized clinical data across a wide range of studies, simplifying cross-cohort analyses.

Within the portal you can explore a dataset, understand its contents, and build custom cohorts for deeper analysis using Jupyter notebooks. AMP PD is a public-private partnership between The Michael J. Fox Foundation, National Institutes of Health, the U.S. Food and Drug Administration, Aligning Science Across Parkinson’s (ASAP), and five companies (Bristol Myers-Squibb, GSK, Pfizer, Sanofi, and Verily). AMP PD is managed through the Foundation of the National Institutes of Health (FNIH). 

AMP PD Datasets

  • BioFIND

    BioFIND is an observational, cross-sectional study with plasma, DNA, and RNA data from blood, whole blood, blood pellet, and cerebrospinal fluid in 118 well-defined, moderately advanced people with Parkinson's and 88 control volunteers.

  • HBS

    The Harvard Biomarkers Study (HBS) is a longitudinal, case-control study of people with memory and movement disorders as well as controls without neurologic disease. A total of 877 HBS participants met the criteria for inclusion in AMP PD. 

  • PDBP

    The Parkinson’s Disease Biomarkers Program (PDBP) includes clinical assessments and biosample data from 1,599 participants with Parkinson's disease or another parkinsonism as well as controls. 

  • PPMI

    The Parkinson’s Progressive Marker’s Initiative (PPMI) is an ongoing longitudinal observational study with more than 1,500 participants contributing comprehensive clinical and genetic data.

AMP PD Resources

  • Webinar and Training Videos: AMP PD offers six webinars and training videos that explain how to use the platform and its components, including Google Cloud Platform (GCP), BigQuery, and Terra. 
Coming Soon!
  • LBD

    Lewy Body Dementia (LBD) genetic data was generated to extend modern gene discovery methods to LBD and create a genetic resource for the dementia research community.


    Data from the STEADY-PD3 trial includes measures of neurological function, Parkinson's severity, cognition, and mood.

  • SURE-PD3

    SURE-PD3 (Study of Urate Elevation in Parkinson's Disease) clinical trial data includes neurological function, Parkinson's severity, cognition, and mood.

  • LCC

    LRRK2 Cohort Consortium (LCC) includes motor and non-motor clinical assessments data as well as genetic data generated from whole blood samples.

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.